New drug combo shows promise for hard-to-treat cancers
NCT ID NCT03798626
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 28 times
Summary
This early-phase study tested a drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer. The goal was to find a safe dose and see if the combination helps control tumor growth. While not a cure, it aims to improve disease control for people with limited options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Melbourne, Victoria, 3000, Australia
-
Novartis Investigative Site
Brussels, 1000, Belgium
-
Novartis Investigative Site
Edegem, 2650, Belgium
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Calgary, Alberta, T2N4N2, Canada
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Santiago, Santiago Metropolitan, 8330074, Chile
-
Novartis Investigative Site
Brno, 656 53, Czechia
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60488, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Nagoya, Aichi-ken, 464 8681, Japan
-
Novartis Investigative Site
Kashiwa, Chiba, 2778577, Japan
-
Novartis Investigative Site
Osaka, Osaka, 5418567, Japan
-
Novartis Investigative Site
Sunto Gun, Shizuoka, 411 8777, Japan
-
Novartis Investigative Site
Bunkyo-ku, Tokyo, 113-8603, Japan
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Madrid, 28050, Spain
-
Novartis Investigative Site
Seville, 41013, Spain
-
Novartis Investigative Site
Valencia, 46010, Spain
-
Novartis Investigative Site
Tainan, 704302, Taiwan
-
Novartis Investigative Site
London, SW3 6JJ, United Kingdom
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
University of California LA
Los Angeles, California, 90095, United States
-
WA Uni School Of Med
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.